Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603327 | 1.00 | PARP1 (0.43) | PARP1CYP19A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24775408 | 0.86 | PARP1 (0.43) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16980530 | 0.84 | HPGD (0.50) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19862551 | 0.84 | PARP1 (0.42) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23995525 | 0.84 | TRPA1 (0.49) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19862566 | 0.84 | PARP1 (0.42) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19862562 | 0.84 | HPGD (0.50) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2603298 | 0.84 | TRPA1 (0.49) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14213446 | 0.84 | CHRNB2 (0.59) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2603280 | 0.84 | CHRNB2 (0.59) | PARP1CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | PARP1 368/4885CYP19A1 427/4885CHRNB2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.